Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07023068
EARLY_PHASE1

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

Sponsor: Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.

Official title: Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-09-28

Completion Date

2027-09-28

Last Updated

2025-06-15

Healthy Volunteers

No

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga-DPA PET/CT

Use 68Ga-DPA PET/CT in the diagnosis of lung cancer

Locations (1)

100730

Beijing, China